Holen Sie sich die Stockscreener-App
8.90
4.09%
-0.38
Handel nachbörslich:
9.03
0.13
+1.46%
Schlusskurs vom Vortag:
$9.28
Offen:
$9.01
24-Stunden-Volumen:
65,528
Relative Volume:
0.02
Marktkapitalisierung:
$14.10M
Einnahmen:
$74,000
Nettoeinkommen (Verlust:
$-13.43M
KGV:
-0.9468
EPS:
-9.4
Netto-Cashflow:
$-10.54M
1W Leistung:
+20.11%
1M Leistung:
+139.89%
6M Leistung:
+69.59%
1J Leistung:
-59.51%
1-Tages-Spanne:
$8.81
$9.52
1-Wochen-Bereich:
$7.45
$10.08
52-Wochen-Spanne:
$0.215
$39.84
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Firmenname
Cyclacel Pharmaceuticals Inc
Sektor
Branche
Telefon
908-517-7330
Adresse
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Vergleichen Sie CYCC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
8.90 | 14.37M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-04-27 | Fortgesetzt | ROTH Capital | Buy |
| 2018-09-07 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-10-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2010-02-04 | Eingeleitet | Roth Capital | Buy |
| 2009-10-28 | Eingeleitet | Merriman | Buy |
| 2008-08-12 | Eingeleitet | Piper Jaffray | Buy |
| 2008-03-12 | Bestätigt | Cantor Fitzgerald | Buy |
| 2008-03-12 | Bestätigt | Collins Stewart | Buy |
| 2008-03-12 | Bestätigt | Needham & Co | Buy |
| 2007-11-27 | Bestätigt | Cantor Fitzgerald | Buy |
| 2007-08-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2007-06-04 | Bestätigt | Needham & Co | Buy |
| 2007-04-23 | Eingeleitet | Lazard Capital | Buy |
| 2007-04-10 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Cyclacel Pharmaceuticals Inc Aktie (CYCC) Neueste Nachrichten
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Pharmaceuticals Slashes Losses to $1.3M, Plans Strategic Malaysian Expansion - Stock Titan
Cyclacel Pharmaceuticals files audited Q1 financials to support S-3 eligibility - Investing.com Canada
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Globe and Mail
What makes Cyclacel Pharmaceuticals Inc. stock price move sharplyFree Momentum Stock List - thegnnews.com
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors - The Globe and Mail
Cyclacel Stock Surges 50% After Amending Exchange Agreement with FITTERS - MSN
Cyclacel (CYCC) Stock Sees Strong Pre-Market Performance After New Study Results - 富途牛牛
Cyclacel Pharmaceuticals Inc. (CYCC) Soars 34.86% on Encouraging Preclinical Results - AInvest
Cyclacel Pharmaceuticals Stock Up 34.6% In Massive After-Hours Rally - Benzinga
Major Shareholder Cashes Out on Cyclacel Pharmaceuticals Stock! - TipRanks
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - The Manila Times
Cyclacel Pharmaceuticals Highlights Promising Preclinical Study on Plogosertib for Treating Biliary Tract Cancer - Quiver Quantitative
Breakthrough: Novel Drug Plogosertib Effectively Targets Aggressive Biliary Cancer, Study Reveals Key Biomarker - Stock Titan
WeightWatchers Reschedules Second Quarter 2025 Earnings Release and Conference Call to Finalize Fresh Start Accounting Adoption in Connection with Emergence - The Globe and Mail
What are the technical indicators suggesting about Cyclacel Pharmaceuticals Inc.Tap into rapid wealth building techniques - Jammu Links News
What are analysts’ price targets for Cyclacel Pharmaceuticals Inc. in the next 12 monthsInvest in stocks with strong fundamentals - Jammu Links News
Is Cyclacel Pharmaceuticals Inc. stock overvalued or undervaluedAchieve breakthrough gains with expert advice - Jammu Links News
What are Cyclacel Pharmaceuticals Inc. company’s key revenue driversDynamic investment opportunities - Jammu Links News
How volatile is Cyclacel Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough gains with smart trades - Jammu Links News
How does Cyclacel Pharmaceuticals Inc. compare to its industry peersUnlock powerful trading tools for investors - Jammu Links News
What is the dividend policy of Cyclacel Pharmaceuticals Inc. stockInvest smarter with actionable stock recommendations - Jammu Links News
What institutional investors are buying Cyclacel Pharmaceuticals Inc. stockHigh-yield investments - Jammu Links News
What drives Cyclacel Pharmaceuticals Inc. stock priceCapitalize on stocks with high profit margins - Jammu Links News
Should I hold or sell Cyclacel Pharmaceuticals Inc. stock in 2025Maximize returns with timely market signals - Jammu Links News
When is Cyclacel Pharmaceuticals Inc. stock expected to show significant growthAchieve breakthrough profits with smart strategies - Jammu Links News
What is the risk reward ratio of investing in Cyclacel Pharmaceuticals Inc. stockGet real-time alerts on top stocks - Jammu Links News
Cyclacel Pharmaceuticals Inc. Stock Analysis and ForecastAchieve consistent profits with smart trading - Jammu Links News
What are the latest earnings results for Cyclacel Pharmaceuticals Inc.Unprecedented growth rates - Jammu Links News
What is Cyclacel Pharmaceuticals Inc. company’s growth strategyGame-changing returns - Jammu Links News
Published on: 2025-08-03 02:26:26 - Jammu Links News
3 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire - The Globe and Mail
MELI Set to Report Q2 earnings: Time to Hold or Fold the Stock? - The Globe and Mail
Is it the right time to buy Cyclacel Pharmaceuticals Inc. stockStock Strategy Recommendation For Every Investor - jammulinksnews.com
IBM Report: Canadians' Data Security Under Increased Threat, While Breach Costs Surge - The Globe and Mail
Using Python tools to backtest Cyclacel Pharmaceuticals Inc. strategiesMomentum Trading Guide with Safety Limits - Newser
What Technical Tools Say About Cyclacel Pharmaceuticals Inc. RecoveryFast Entry High Potential Stock Alerts Triggered - metal.it
Verisign’s Earnings Call: Strong Growth Amid Caution - The Globe and Mail
Celestica Beats Q2 Earnings Estimates on Solid Top-Line Growth - The Globe and Mail
How high can Cyclacel Pharmaceuticals Inc. stock goAI Trade Signal Forecast with Chart Logic - Newser
Custom strategy builders for tracking Cyclacel Pharmaceuticals Inc.Free Daily Momentum Screener With Alerts - Newser
Cyclacel Pharmaceuticals Inc. recovery potential after sell offWeekly Gain Forecast with Momentum Indicators - Newser
Full technical analysis of Cyclacel Pharmaceuticals Inc. stockProven Trading System with Consistent Gains - Newser
What the charts say about Cyclacel Pharmaceuticals Inc. todayConservative Asset Allocation Risk Analysis - Newser
Why Cyclacel Pharmaceuticals Inc. stock attracts strong analyst attentionReal-Time Entry Signals for Top Stocks - Newser
Is Cyclacel Pharmaceuticals Inc. Starting a New UptrendSector Based Breakout Stock Forecast Issued - metal.it
Cyclacel Pharmaceuticals Amends Series F Stock Limitations - TipRanks
How strong is Cyclacel Pharmaceuticals Inc. company’s balance sheetExpert Picks Tips With High Returns - Jammu Links News
Does Cyclacel Pharmaceuticals Inc. stock perform well during market downturnsHigh-profit stock alerts - Jammu Links News
Finanzdaten der Cyclacel Pharmaceuticals Inc-Aktie (CYCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cyclacel Pharmaceuticals Inc-Aktie (CYCC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lazar David E. | Interim CEO |
Feb 26 '25 |
Sale |
0.03 |
194,628,820 |
5,507,996 |
0 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):